en · de · es · fr · pt
liraglutide-notes.peptides1004.com › Faq › Receptor Pharmacology And Mechanism — Background and Details

Receptor Pharmacology And Mechanism — Background and Details

By Editorial Desk · published 2026-05-05 · last reviewed 2026-05-21 · Faq

cyclic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.

Receptor Pharmacology And Mechanism

Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.

How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.

Identity and Chemical Background

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Pt-141 at a glance

PropertyValueNotes
Primary receptor targetMC4R agonistSubtype most often linked to behavioural effects
Other reported targetsMC1R, MC3R, MC5RActivity is not selective for a single subtype
Endogenous ligand classMelanocortin peptidesAlpha-MSH and ACTH act on the same family
Peptide architectureCyclic heptapeptideLactam bridge between the aspartate and lysine residues
Central actionInferred from animal modelsNot directly measured in the human brain

Receptor Pharmacology and Study Measures

Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.

Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.

Related pages on this site

Bremelanotide Background and Receptor Pharmacology

Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.

PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Supporting material

He ended the 2000s by producing director Jaume Collet-Serra's psychological horror thriller film Orphan (2009), starring Vera Farmiga, Peter Sarsgaard and Isabelle Fuhrman. Although the film received mixed reviews, it was a commercial success.

CMS – Centers for Medicare & Medicaid Services. Their objective would be to strengthen health equity, expand coverage, and improve health outcomes. License: Pursuant to Section 353 of the Public Health Services Act (42 U.S.C. 263a) as revised by the Clinical Laboratory Improvement Amendments (CLIA).

=== Cleavage and ligation === In addition to those listed above, the most important modification of primary structure is peptide cleavage (by chemical hydrolysis or by proteases). Proteins are often synthesized in an inactive precursor form; typically, an N-terminal or C-terminal segment blocks the active site of the protein, inhibiting its function. The protein is activated by cleaving off the inhibitory peptide. Some proteins even have the power to cleave themselves. Typically, the hydroxyl group of a serine (rarely, threonine) or the thiol group of a cysteine residue will attack the carbonyl carbon of the preceding peptide bond, forming a tetrahedrally bonded intermediate [classified as a hydroxyoxazolidine (Ser/Thr) or hydroxythiazolidine (Cys) intermediate]. This intermediate tends to revert to the amide form, expelling the attacking group, since the amide form is usually favored by free energy, (presumably due to the strong resonance stabilization of the peptide group). However, additional molecular interactions may render the amide form less stable; the amino group is expelled instead, resulting in an ester (Ser/Thr) or thioester (Cys) bond in place of the peptide bond. This chemical reaction is called an N-O acyl shift. The ester/thioester bond can be resolved in several ways:

=== Pharmacokinetics === The pharmacokinetics of SR-17018 in rodents have been studied. In mice, it is orally active, showing 69% bioavailability, has an elimination half-life of approximately 6 hours, and efficiently crosses the blood–brain barrier into the central nervous system. The drug has greatly improved bioavailability orally compared to intraperitoneally in mice. Its half-life in mice is longer than that of morphine or oxycodone. Similarly, its duration is longer than that of morphine or fentanyl in mice.

=== Inhibition of methylation === After azanucleosides such as azacitidine have been metabolized to 5-aza-2′-deoxycytidine-triphosphate (decitabine-triphosphate), they can be incorporated into DNA and azacytosine can be substituted for cytosine. Azacytosine-guanine dinucleotides are recognized as substrate by the DNA methyltransferases, which catalyze the methylation reaction by a nucleophilic attack. This results in a covalent bond between the carbon-6 atom of the cytosine ring and the enzyme. The bond is normally resolved by beta-elimination through the carbon-5 atom, but this latter reaction does not occur with azacytosine because its carbon-5 is substituted by nitrogen, leaving the enzyme covalently bound to DNA and blocking its DNA methyltransferase function. In addition, the covalent protein adduction also compromises the functionality of DNA and triggers DNA damage signaling, resulting in the degradation of trapped DNA methyltransferases. As a consequence, methylation marks become lost during DNA replication.

Sources: en.wikipedia.org

Notes from published material

The findings of drug discrimination tests suggest that 5-HTP has a more complex or compound discriminative stimulus compared to other agents like LSD and that its stimulus properties may not be readily explained by either the serotonin 5-HT1 or 5-HT2 receptors alone. Instead, a combination of actions at these and/or other receptors may be involved in its stimulus effects.

As part of supply provisions within the Comecon, Lot was allocated four Il-86s as barter for component manufacture; the airline deferred deliveries which were cancelled by 1987. In 1988 the East German airline Interflug is said to have prepared to take delivery of two Il-86s and to have allocated them the registrations DDR-AAA and DDR-AAB. Instead, that same year the airline took delivery of two Airbus A310s. The sole export order for the Il-86 − and the sole commercial transactions involving factory-built rather than secondhand examples − was by China Xinjiang Airlines which received three aircraft in 1990. The first Il-86 to be built was displayed at the Paris Salon International de l'Aéronautique in 1977. It was noted that its interior used patented fire-resistant materials and hydraulics employed a fire-resistant fluid. At that time a version without the "luggage at hand" system was offered, seating 375 or alternatively weighing 3,000 kg (6,600 lb) less and having longer range. This version offered 7% lower seat-mile operational costs. The type was again displayed at Paris in 1979, 1981, 1983 and 1985, the Farnborough Air Show in 1984 and other world air events. Setting records was a traditional Soviet way of promoting aviation products. On Tuesday September 22, 1981, an Il-86 flown by Commander G Volokhov and Second Pilot A Tyuryumin set Fédération Aéronautique Internationale records for flying payloads of 35, 40, 45, 50, 55, 60 and 65 tonnes over a 2,000 km closed circuit at an average of 975.3 km per hour.

== Cancer == DPEP1 has been found to be highly expressed in colon tumor cells compared to normal colon cells—one study even found a ≥2 fold over-expression of DPEP1. Increased levels of DPEP1 have also been detected in colorectal cancer patients, suggesting that DPEP1 is a viable marker for disseminated colon tumor cells.

== Habitat == The Turkestan cockroach is primarily an outdoor insect, not known as an aggressive indoor pest, unlike some cockroach species such as the German and brown-banded cockroaches, though it will inhabit areas around dwellings where shelter can be found. However, in specific localities or tropical locations, it can become a significant indoor pest. Of occasional indoor interlopers, males are more commonly encountered than females, due to their ability to fly and an attraction to lights. In Arabia, it lives beneath stones in damp hollows, desert farms, and wadis, feeding primarily at night.

==== Cleaved, contracted, and expanded rings ==== Secosteroids (Latin seco, "to cut") are a subclass of steroidal compounds resulting, biosynthetically or conceptually, from scission (cleavage) of parent steroid rings (generally one of the four). Major secosteroid subclasses are defined by the steroid carbon atoms where this scission has taken place. For instance, the prototypical secosteroid cholecalciferol, vitamin D3 (shown), is in the 9,10-secosteroid subclass and derives from the cleavage of carbon atoms C-9 and C-10 of the steroid B-ring; 5,6-secosteroids and 13,14-steroids are similar. Norsteroids (nor-, L. norma; "normal" in chemistry, indicating carbon removal) and homosteroids (homo-, Greek homos; "same", indicating carbon addition) are structural subclasses of steroids formed from biosynthetic steps. The former involves enzymic ring expansion-contraction reactions, and the latter is accomplished (biomimetically) or (more frequently) through ring closures of acyclic precursors with more (or fewer) ring atoms than the parent steroid framework. Combinations of these ring alterations are known in nature. For instance, ewes who graze on corn lily ingest cyclopamine (shown) and veratramine, two of a sub-family of steroids where the C- and D-rings are contracted and expanded respectively via a biosynthetic migration of the original C-13 atom. Ingestion of these C-nor-D-homosteroids results in birth defects in lambs: cyclopia from cyclopamine and leg deformity from veratramine. A further C-nor-D-homosteroid (nakiterpiosin) is excreted by Okinawan cyanobacteriosponges.

Sources: en.wikipedia.org

Further detail

Choline is an essential nutrient. The cholines are a family of water-soluble quaternary ammonium compounds. Choline is the parent compound of the cholines class, consisting of ethanolamine having three methyl substituents attached to the amino function. Healthy humans fed artificially composed diets that are deficient in choline develop fatty liver, liver damage, and muscle damage. Choline was not initially classified as essential because the human body can produce choline in small amounts through phosphatidylcholine metabolism.

=== 1995 leadership election === John Major was consistently opposed by Eurosceptics in his party (known as the Maastricht Rebels – a small minority of MPs before 1997, but enjoying much wider support among party activists). Heseltine always stated categorically that he would never stand for party leader against Major. In mid-1995 Major challenged his critics to "put up or shut up" by resubmitting himself to a leadership election in which he was unsuccessfully opposed by John Redwood the Secretary of State for Wales. There was speculation that Heseltine's supporters would engineer Major's downfall in the hope that their man would take over, but they stayed loyal to Major. Heseltine had been listening to regular reports about his potential support from his lieutenants Keith Hampson, Richard Ottaway, Michael Mates and Peter Temple-Morris, and in the event of a second ballot hoped to receive Major's endorsement. Peter Tapsell refused to support him because of the European issue. Hampson believed that Heseltine might have won, as did Philip Stephens of the Financial Times. Michael Crick does not agree, pointing out that many of Heseltine's supporters from 1990 had retired from the Commons and the 1992 intake was more right-wing and eurosceptic. Heseltine, who showed his ballot paper to the returning officers to prove that he had voted for Major, commented that "John Major deserves a great deal better than that from his colleagues". Major was re-elected leader.

=== Ab–Ah === John Jacob Abel (1857–1938). American biochemist and pharmacologist. He founded and chaired the first department of pharmacology in the United States at the University of Michigan. Robert Abeles (1926–2000). American biological chemist at Brandeis University. Member Natl. Acad. Sci. USA. John Abelson (b. 1938). American biologist at Caltech, with expertise in biophysics, biochemistry, and genetics, and known for work on RNA splicing. Sir Edward Abraham CBE, FRS (1913–1999). English biochemist at the University of Oxford involved in the development of penicillin and cephalosporin Gary Ackers (1939–2011). American Professor of Biochemistry and Molecular Biophysics at Washington University in St. Louis, who worked on thermodynamic linkage analysis of biological macromolecules. Gilbert Smithson Adair FRS (1896–1979). British protein chemist at the University of Cambridge, the first to identify cooperative binding, in the context of oxygen binding to haemoglobin. Julius Adler (1930–2024). American Professor of Biochemistry and Genetics at the University of Wisconsin–Madison, known for work on chemotaxis. David Agard (20th–21st century). American Professor of Biochemistry and Biophysics at UC San Francisco, whose research is focussed on understanding the basic principles of macromolecular structure and function. Member Natl. Acad. Sci. USA. Natalie Ahn (PhD 1985).

=== Angular velocity === A MERU (milli Earth rate unit) is a measure of angular velocity equal to 1⁄1000 of Earth's rotation rate: 1 MERU = 7.292115×10^−8 radians per second or about 0.2625 milliradians/hour. It was introduced by MIT's Instrumentation Laboratories (now Draper Labs) to measure the performance of inertial navigation systems.

== Chemically modified nucleotides == Recently, SELEX has expanded to include the use of chemically modified nucleotides. These chemically modified oligonucleotides offer many potential advantages for selected aptamers including greater stability and nuclease resistance, enhanced binding for select targets, expanded physical properties - like increased hydrophobicity, and more diverse structural conformations. The genetic alphabet, and thus possible aptamers, is also expanded using unnatural base pairs the use of these unnatural base pairs was applied to SELEX and high affinity DNA aptamers were generated.

Sources: en.wikipedia.org

Frequently asked questions

Which receptor does PT-141 act on?

Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.

Does PT-141 act by increasing blood flow?

It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.

Why is the mechanism described as uncertain?

Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.

What is PT-141?

PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.

Network